This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Reddy, K. B. Articles by Osborne, C. K. Search for Related Content PubMed PubMed Citation Articles by Reddy, K. B. Articles by Osborne, C. K.

Inhibition of Breast Cancer Cell Growth in Vitro by a Tyrosine Kinase Inhibitor¹

Department of Medicine, Divisions of Medical Oncology [K. B. R., G. L. M., A. K. T., C. K. O.] and Endocrinology [T. Y., G. R. M.], University of Texas Health Science Center at San Antonio, San Antonio, Texas 78284, and Rhone-Poulenc Rorer, King of Prussia, Pennsylvania 19406 [A. Z.]

Human breast cancer cell proliferation is regulated by growth factors that bind to receptors with intrinsic tyrosine kinase (TK) activity, including the epidermal growth factor (EGF) receptor. To determine whether inhibition of receptor TK activity inhibits tumor growth, we studied the effects of a tyrosine kinase inhibitor, RG-13022, on cultured human breast cancer cells. RG-13022 represents a class of compounds which have been shown to inhibit preferentially the TK activity of the EGF receptor in a cell-free system and also to inhibit EGF-stimulated growth of cultured cells. RG-13022 significantly inhibited EGF-stimulated autophosphorylation of its receptor in two breast cancer cell lines that have abundant, although not amplified, EGF receptor content (MDA-231 and T47D). RG-13022 also inhibited EGF-stimulated DNA synthesis and proliferation of T47D and MCF-7 breast cancer cells in a reversible and dose-dependent manner. Inhibition was observed at 0.1 µM, and it was maximal at 10 µM. The effect was rapid (within 3 h), persisted for 18 h, and was partially reversed by 24 h at 1 µM. At 5 µM, inhibition persisted for more than 50 h. Inhibitory effects were also observed in a panel of estrogen receptor-positive and estrogen receptor-negative breast cancer cell lines. RG-13022 inhibited not only EGF-induced growth but also growth stimulated by insulin, insulin-like growth factor I, insulin-like growth factor II, or transforming growth factor . RG-13022 also totally blocked estrogen-stimulated phosphorylation of the EGF receptor, as well as estrogen-induced cell proliferation, suggesting that functioning TK pathways are required for estrogen action. The TK inhibitor RG-13022 is a potent inhibitor of hormonally regulated growth of human breast cancer. Tyrosine kinase inhibitors have the potential of providing a new strategy for the "endocrine therapy" of breast cancer.

¹ This work was supported in part by NIH Grants CA-30195, AR-39529, CA-40035, and DE-08569.

² Present address: BioGenex Laboratories, 4600 Norris Canyon, San Ramon, CA 94583.

³ To whom requests for reprints should be addressed, at Department of Medicine/Medical Oncology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78284-7884.

Received 7/25/91. Accepted 4/20/92.

This article has been cited by other articles:

				M. De Laurentiis, G. Arpino, E. Massarelli, A. Ruggiero, C. Carlomagno, F. Ciardiello, G. Tortora, D. D'Agostino, F. Caputo, G. Cancello, et al. A Meta-Analysis on the Interaction between HER-2 Expression and Response to Endocrine Treatment in Advanced Breast Cancer Clin. Cancer Res., July 1, 2005; 11(13): 4741 - 4748. [Abstract] [Full Text] [PDF]

				J. S. Kruger and K. B. Reddy Distinct Mechanisms Mediate the Initial and Sustained Phases of Cell Migration in Epidermal Growth Factor Receptor-Overexpressing Cells Mol. Cancer Res., September 1, 2003; 1(11): 801 - 809. [Abstract] [Full Text] [PDF]

				V. G. Keshamouni, R. R. Mattingly, and K. B. Reddy Mechanism of 17-beta -Estradiol-induced Erk1/2 Activation in Breast Cancer Cells. A ROLE FOR HER2 AND PKC-delta J. Biol. Chem., June 14, 2002; 277(25): 22558 - 22565. [Abstract] [Full Text] [PDF]

				M. Singh, G. Setalo Jr, X. Guan, M. Warren, and C. D. Toran-Allerand Estrogen-Induced Activation of Mitogen-Activated Protein Kinase in Cerebral Cortical Explants: Convergence of Estrogen and Neurotrophin Signaling Pathways J. Neurosci., February 15, 1999; 19(4): 1179 - 1188. [Abstract] [Full Text] [PDF]

				T. H. Jones, S. K. Justice, and A. Price Suppression of Tyrosine Kinase Activity Inhibits [3H]Thymidine Uptake in Cultured Human Pituitary Tumor Cells J. Clin. Endocrinol. Metab., July 1, 1997; 82(7): 2143 - 2147. [Abstract] [Full Text] [PDF]

				A Levitzki and A Gazit Tyrosine kinase inhibition: an approach to drug development Science, March 24, 1995; 267(5205): 1782 - 1788. [Abstract] [PDF]